GABAA receptor-binding protein promotes sensitivity to apoptosis induced by chemotherapeutic agents

Seung Bae Rho1, Hyun-Jung Byun, Boh-Ram Kim

  • 1Research Institute, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, Republic of Korea. sbrho@ncc.re.kr

Insights

Human gamma-aminobutyrate type A receptor-binding protein (GABARBP) acts as a pro-apoptotic protein in ovarian cancer. Combined with cisplatin, GABARBP enhances apoptosis and inhibits cancer cell proliferation and migration.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer remains a significant health challenge with limited treatment options.
  • Understanding novel therapeutic targets and mechanisms is crucial for improving patient outcomes.
  • The role of gamma-aminobutyrate type A receptor-binding protein (GABARBP) in cancer is not fully elucidated.

Purpose of the Study:

  • To investigate the expression and function of GABARBP in ovarian cancer.
  • To evaluate the potential of GABARBP as a therapeutic agent, alone and in combination with cisplatin.
  • To elucidate the molecular mechanisms underlying GABARBP's effects on ovarian cancer cells.

Main Methods:

  • Analysis of GABARBP expression in ovarian cancer cell lines and tissues.
  • Cell proliferation, migration, and apoptosis assays.
  • Western blotting to assess protein expression levels (cyclin D1, CDK4, p53, p21, Bcl-2, Bcl-xL).
  • Luciferase reporter assays to evaluate promoter activity (p53, p21).
  • Validation of p53 activity using UV irradiation and small interfering RNA (siGABARBP).

Main Results:

  • GABARBP expression is downregulated in ovarian cancer.
  • GABARBP exhibits pro-apoptotic properties and suppresses cancer cell proliferation and migration.
  • Combined treatment with GABARBP and cisplatin demonstrates synergistic effects on inhibiting cell growth and migration.
  • The combination therapy downregulates cyclin D1 and CDK4, arrests the cell cycle in G₀-G₁, and modulates apoptosis-related proteins (p53, p21, Bcl-2, Bcl-xL).
  • GABARBP induces p53 and p21 promoter activity, indicating a role in p53-mediated apoptosis.

Conclusions:

  • GABARBP is a novel pro-apoptotic protein with potential in ovarian cancer therapy.
  • GABARBP enhances the anti-cancer effects of cisplatin through p53-dependent pathways.
  • Targeting GABARBP may represent a promising strategy for ovarian cancer treatment.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...